Eli Lilly and Co (LLY) : Rhenman Partners Asset Management Ab scooped up 40,000 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 235,000 shares of Eli Lilly and Co which is valued at $19,439,200.Eli Lilly and Co makes up approximately 3.11% of Rhenman Partners Asset Management Ab’s portfolio.
Other Hedge Funds, Including , Zurcher Kantonalbank (zurich Cantonalbank) reduced its stake in LLY by selling 26,855 shares or 11.61% in the most recent quarter. The Hedge Fund company now holds 204,553 shares of LLY which is valued at $16,920,624. Eli Lilly and Co makes up approx 0.22% of Zurcher Kantonalbank (zurich Cantonalbank)’s portfolio.Sigma Planning Corp boosted its stake in LLY in the latest quarter, The investment management firm added 149 additional shares and now holds a total of 13,229 shares of Eli Lilly and Co which is valued at $1,079,354. Eli Lilly and Co makes up approx 0.14% of Sigma Planning Corp’s portfolio.Bender Robert Associates reduced its stake in LLY by selling 370 shares or 5.62% in the most recent quarter. The Hedge Fund company now holds 6,216 shares of LLY which is valued at $507,163. Eli Lilly and Co makes up approx 0.34% of Bender Robert Associates’s portfolio.James Investment Research Inc reduced its stake in LLY by selling 362,472 shares or 48.31% in the most recent quarter. The Hedge Fund company now holds 387,854 shares of LLY which is valued at $31,008,927. Eli Lilly and Co makes up approx 0.77% of James Investment Research Inc’s portfolio.Jacobs Coca reduced its stake in LLY by selling 965 shares or 1.96% in the most recent quarter. The Hedge Fund company now holds 48,389 shares of LLY which is valued at $3,840,151. Eli Lilly and Co makes up approx 0.88% of Jacobs Coca’s portfolio.
Eli Lilly and Co closed down -0.3 points or -0.36% at $82.42 with 20,93,793 shares getting traded on Thursday. Post opening the session at $83.02, the shares hit an intraday low of $82.37 and an intraday high of $83.02 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.